Dendreon -- a biotech company that receives a lot of attention on Fool.com and is hotly debated as a stock -- has recently announced that it will be making an aggressive direct-to-consumer marketing push. In the following video, Motley Fool health care analyst David Williamson explains what this means for investors and what he is looking for in a national ad campaign.
Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors? David answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.
The article Dendreon's Big New Push originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Follow him on Twitter @MotleyDavid. Max Macaluso has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.